Virios completes enrollment in IMC-2 Phase 2 Long COVID study

Virios Therapeutics announced that the Bateman Horne Center has completed enrollment in its investigator-initiated, proof of concept LC study. Top line data from this study are projected to be released in October 2024. The BHC study is a randomized, double-blind, placebo-controlled evaluation of the combination of valacyclovir and celecoxib as a treatment for fatigue and other symptoms associated with LC illness. This study follows on from a positive prior investigator-initiated proof of concept study demonstrating that the valacyclovir/celecoxib combination improved fatigue, pain, orthostatic symptoms, anxiety and overall patient LC health when compared with an untreated control group of patients matched by age, gender, COVID vaccination rates and duration of illness.